Modulation of Pathological Pain by Epidermal Growth Factor Receptor
Open Access
- 12 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
Abstract
Chronic pain has been widely recognized as a major public health problem that impacts multiple aspects of patient quality of life. Unfortunately, chronic pain is often resistant to conventional analgesics, which are further limited by their various side effects. New therapeutic strategies and targets are needed to better serve the millions of people suffering from this devastating disease. To this end, recent clinical and preclinical studies have implicated the epidermal growth factor receptor signaling pathway in chronic pain states. EGFR is one of four members of the ErbB family of receptor tyrosine kinases that have key roles in development and the progression of many cancers. EGFR functions by activating many intracellular signalling pathways following binding of various ligands to the receptor. Several of these signalling pathways, such as phosphatidylinositol 3-kinase (PI3K), are known mediators of pain. EGFR inhibitors are known for their use as cancer therapeutics but given recent evidence in pilot clinical and preclinical investigations, may have clinical use for treating chronic pain. Here, we review the clinical and preclinical evidence implicating EGFR in pathological pain states and provide an overview of EGFR signalling highlighting how EGFR and its ligands drive pain hypersensitivity and interact with important pain pathways such as the opioid system.Funding Information
- International Anesthesia Research Society
- Canadian Institutes of Health Research (PJT-156355)
This publication has 197 references indexed in Scilit:
- Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locationsCancer Letters, 2012
- Blockade of PDGFR-β activation eliminates morphine analgesic toleranceNature Medicine, 2012
- Summary of Findings from the OPPERA Baseline Case-Control Study: Implications and Future DirectionsThe Journal of Pain, 2011
- Orofacial Pain Prospective Evaluation and Risk Assessment Study – The OPPERA StudyThe Journal of Pain, 2011
- Akt1 interacts with epidermal growth factor receptors and hedgehog signaling to increase stem/transit amplifying cells in the embryonic mouse cortexDevelopmental Neurobiology, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Cellular and Molecular Mechanisms of PainCell, 2009
- Matrix metalloprotease regulation of neuropathic painTrends in Pharmacological Sciences, 2009
- Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for DegradationDevelopmental Cell, 2008
- Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1Molecular and Cellular Neuroscience, 2007